Publications by authors named "Timothy M Schmidt"

Claim this Profile
R
Rapid PET/MRI to Assess Multiple Myeloma Using T2-Weighted Imaging With Uniform Fat Suppression.
Rianne A van der Heijden, Timothy M Schmidt, Lu Mao, Natallie S Callander, Diego Hernando

J Comput Assist Tomogr· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?
Timothy M Schmidt

Blood Cancer J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Natalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, Kelly N Godby, Jacob Laubach, Timothy M Schmidt

Blood Cancer J· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD1TIGIT2B4KLRG1 Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy.
Ameet K Mishra, Timothy M Schmidt, Ella B Martell, Alex S Chen, Reyna E Dogru

Transplant Cell Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Luciano J Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R Dholaria, Timothy M Schmidt

Lancet Haematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Making a case for del(1p) as a high-risk abnormality in multiple myeloma.
Timothy M Schmidt

Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation.
Rebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, Binod Dhakal, Bhagirathbhai Dholaria

EJHaem· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy.
Susan Bal, Timothy M Schmidt, Luciano J Costa, Natalie S Callander

Leuk Lymphoma· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High or low? Assessing disease risk in multiple myeloma.
Timothy Martin Schmidt

Hematology Am Soc Hematol Educ Program· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Luciano J Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R Dholaria, Timothy M Schmidt

J Clin Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapy.
Susan Bal, Binod Dhakal, Rebecca W Silbermann, Timothy M Schmidt, Bhagirathbhai Dholaria

Am J Hematol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agent myeloma has a new weapon from (ch1)Q.
Timothy M Schmidt, Lawrence H Boise

Blood· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chromosome 1q21 abnormalities in multiple myeloma.
Timothy M Schmidt, Rafael Fonseca, Saad Z Usmani

Blood Cancer J· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progress in the Management of Smoldering Multiple Myeloma.
Timothy M Schmidt, Natalie S Callander

Curr Hematol Malig Rep· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.
Timothy M Schmidt, Benjamin G Barwick, Nisha Joseph, Leonard T Heffner, Craig C Hofmeister

Blood Cancer J· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
Timothy M Schmidt, L I Liu, Ivy E Abraham, Almae B Uy, Arkadiusz Z Dudek

Anticancer Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis